Side-by-side · Research reference
KPVvsThymosin α-1
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-StrongDraft13/39 cited
BPhase 3Reviewed8/39 cited
KPV
α-MSH C-terminal · Anti-inflammatory
SQ / oral / topical · Local · Daily or 2-3×/week
Thymosin α-1
Immune modulator · Approved (some countries)
SQ · 2× weekly · 6+ months for chronic indications
01Mechanism of Action
Parameter
KPV
Thymosin α-1
Primary target
Intracellular targets bypassing melanocortin receptors (proposed)Dalle-Pang 2024
Toll-like receptor 9 (TLR9) + T-cell maturation pathwayCamerini 2001
Pathway
NF-κB inhibition + cytokine modulation (TNF-α, IL-1β, IL-6) → reduced inflammationDalle-Pang 2024
TLR9 activation → ↑ IFN-α + IL-2 + IFN-γ → enhanced T-cell function + dendritic cell maturationIyer 2007
Downstream effect
Anti-inflammatory action without α-MSH pigmentation effects; gut barrier protectionDalle-Pang 2024
Restored T-cell function, improved viral clearance, anti-tumour adjuvant effectsIyer 2007
Feedback intact?
No melanocortin receptor binding
—
Origin
Synthetic tripeptide; the C-terminal Lys-Pro-Val residues of α-MSH (residues 11-13)Dalle-Pang 2024
Synthetic 28-AA peptide identical to natural Tα-1 isolated from thymus extractCamerini 2001
Antibody development
—
—
02Dosage Protocols
Parameter
KPV
Thymosin α-1
Frequency
Daily or 2–3× per week
2× weekly (Mon/Thu typical)
Lower / starter dose
100 mcg / day
0.8 mg per injection
Evidence basis
Animal-strong + emerging clinical data in IBDDalle-Pang 2024
Phase 3 + approved (35+ countries as Zadaxin)Iyer 2007
Duration
4–8 weeks per cycle
6–12 months for chronic indications
Reconstitution
Bacteriostatic water (SQ form)
Sterile water for injection per vial label
Timing
No specific time; often taken with / before meals (oral)
No specific time
Half-life
Hours (estimated; rapid tissue uptake)
~2 hours plasma; tissue effect days
04Side Effects & Safety
Parameter
KPV
Thymosin α-1
Injection site reaction
Mild irritation
Erythema, mild discomfort
GI symptoms
Rare nausea (oral form)
Rare nausea
Long-term safety
Limited human data
—
Pregnancy / OB
Avoid — insufficient data
Avoid
Fatigue
—
Common during initial weeks
Fever / flu-like
—
Mild interferon-like response possible
Autoimmune
—
Theoretical risk; caution in active autoimmune disease
Cancer risk
—
No signal — used as adjuvant in oncology
Absolute Contraindications
KPV
- ·Pregnancy / breastfeeding
Thymosin α-1
- ·Pregnancy / breastfeeding
- ·Hypersensitivity to peptide
- ·Concurrent immunosuppressant therapy (transplant patients)
Relative Contraindications
KPV
- ·Active autoimmune disease (theoretical)
Thymosin α-1
- ·Active autoimmune disease
- ·Severe immunocompromised state without supervision
05Administration Protocol
Parameter
KPV
Thymosin α-1
1. Reconstitution
Add 1 mL bacteriostatic water to vial per labelling.
Add 1 mL sterile water per 1.6 mg vial → 1.6 mg/mL.
2. Form
SQ injection (acute), oral capsule (chronic / gut), topical for skin indications.
SQ — abdomen, thigh, or upper arm. Rotate sites.
3. Timing
Morning preferred; oral form taken with / before meals.
2× weekly, e.g. Monday + Thursday.
4. Storage
Lyophilised: room temp, light-protected. Reconstituted: refrigerate ≤30 days.
Lyophilised: refrigerate. Reconstituted: refrigerate, use within 24 h.
5. Needle
29–31G insulin syringe (SQ form).
27–31G, 4–8 mm insulin syringe.
06Stack Synergy
KPV
+ BPC-157
StrongKPV (NF-κB inhibition, cytokine reduction) + BPC-157 (VEGF-driven angiogenesis, tissue regeneration) form the classic gut-healing stack. KPV reduces inflammatory drive; BPC-157 promotes mucosal repair. Anecdotally favoured for IBD, ulcerative colitis, and post-surgical gut recovery.
- KPV
- 200–500 mcg oral · daily
- BPC-157
- 250–500 mcg oral or SQ · daily
- Primary benefit
- Combined anti-inflammation + mucosal repair for gut conditions
Thymosin α-1
— no documented stacks